Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
368
datasets available to search
ShareScore release 0.9.0
Dataset results
368 results for “Hepatitis B virus”
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
ClinicalTrials.gov study NCT02166047. IPD Sharing: Not stated. Countries: 6. Publications: 2.
Arresting Vertical Transmission of Hepatitis B Virus
ClinicalTrials.gov study NCT03567382. IPD Sharing: NO. Countries: 1. Publications: 1.
Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System
ClinicalTrials.gov study NCT01777295. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
ClinicalTrials.gov study NCT04129554. IPD Sharing: YES. Countries: 7. Publications: 1.
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
ClinicalTrials.gov study NCT03365947. IPD Sharing: NO. Countries: 3. Publications: 2.
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
ClinicalTrials.gov study NCT03762681. IPD Sharing: YES. Countries: 7. Publications: 1.
Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand
ClinicalTrials.gov study NCT01745822. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
ClinicalTrials.gov study NCT00307489. IPD Sharing: Not stated. Countries: 4. Publications: 6.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Part
ClinicalTrials.gov study NCT02952924. IPD Sharing: Not stated. Countries: 8. Publications: 2.
Data from: Telbivudine on IgG-associated Hypergammaglobulinemia and TGF-β1 Hyperactivity in Hepatitis B Virus-related Liver Cirrhosis
<p>Patients' demography, clinical data, serum IgG-Fc glycan profiles, and cytokine profiles ar baseline and week 48 after treatment.</p>
Data from: Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and non-injection drug users from coastal Kenya
Background: Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected injection and non-injection drug users (IDUs) in Kenya remains elusive. Methods: A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48), and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma samples and genotypes established by nested-PCR and direct sequencing. Results: HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly, HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1 infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic (5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected (6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected (7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing minimal diversity was detected among the study participants. Conclusion: HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections. Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high and low risk populations of Kenya.
Simulated hepatitis B virus (HBV) sequencing data and HBV sequence variation graph materials
<p>Simulated HBV sequencing data (InSilicoSeq, HiSeq error model) and a sequence variation graph constructed using HBV genome sequences described in <a href="https://doi.org/10.1099/jgv.0.001387">https://doi.org/10.1099/jgv.0.001387</a></p>
Gut microbiota as mediator and moderator between hepatitis B virus and hepatocellular carcinoma
<p>A STORMS (Strengthening The Organizing and Reporting of Microbiome Studies) checklist is available here.</p>
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
ClinicalTrials.gov study NCT00768157. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
ClinicalTrials.gov study NCT02241590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
ClinicalTrials.gov study NCT00305019. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
ClinicalTrials.gov study NCT00663182. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
ClinicalTrials.gov study NCT02058108. IPD Sharing: YES. Countries: 7. Publications: 0.
Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation
ClinicalTrials.gov study NCT01139203. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People
ClinicalTrials.gov study NCT00100633. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.